Takeover Fever Struck Achillion, but AbbVie’s Still Way Out in Front
Insights - Achillion Pharmaceuticals (ACHN) has been all over the news in the last week (and up more than 100%), the latest target of takeover fever in … Continue Reading
Read NowInsights
More Federal Tax Dollars Slip Away as Medtronic Buys Covidien
Insights - Medtronic (MDT) announced Sunday an agreement to buy Covidien (COV) in a $42.9 billion dollar cash and stock deal. The 29% premium is thought to … Continue Reading
Read Now
bluebird bio’s Treatment for a Rare Blood Disorder is Working
Insights - bluebird bio (BLUE) reported that two patients taking LentiGlobin had rapid and sustained responses to the gene therapy
Read Now
Geron Trials Still on Hold While Collaborator Gets the Greenlight
Insights - Geron Corporation (GERN) announced on Thursday that the FDA has lifted a clinical hold on one trial of lead drug candidate, imetelstat, in myelofibrosis. Though … Continue Reading
Read Now
Another Big Day for Achillion, FDA Yellow-Lights Sovaprevir
Insights - Shares of Achillion Pharmaceuticals (ACHN) are up another 60% on Tuesday, adding to gains that coincided with Monday’s acquisition of fellow early HCV competitor, Idenix Pharmaceutical (IDIX). The stock is up 125% for … Continue Reading
Read Now
Market Ripples from Merck’s Acquisition of Idenix
Insights - The announcement that Merck (MRK) plans to acquire Idenix Pharmaceuticals (IDIX) for $3.85 billion, or $24.50 per share, is having a ripple effect on the … Continue Reading
Read Now
Retrophin Insider Sale Isn’t Winning Over Any Critics
Insights - In an SEC filing on Wednesday, Retrophin (RTRX) CEO Martin Shkreli reported the sale of 292,400 shares of RTRX common stock worth $4.4 million dollars last Friday, nearly 10% … Continue Reading
Read Now